Ruby John Anto (Ruby Anto, Ruby J Anto)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 9

Top Topics

Basal Cell Carcinoma

Anti Inflammatory

Top Venues

Exploration of targeted anti-tumor therapy

Current medicinal chemistry

Cellular and molecular life sciences : CMLS

This page only lists publications with an associated author ORCID identifier.

Publications

Chenicheri Kizhakkeveettil Keerthana, Sreekumar U Aiswarya, Tennyson P Rayginia, Yadu Vijayan, Shirley James, Sadiq C Shifana, Sankar Sundaram, D K Induja, Ravi S Lankalapalli, Kuzhuvelil B Harikumar, Ruby John Anto
A Novel Combinatorial Regimen Using Sorafenib and Uttroside B, A US FDA-designated 'Orphan Drug', for the Treatment of Hepatocellular Carcinoma. Anti-cancer agents in medicinal chemistry (2024)
Tennyson P Rayginia, Chenicheri K Keerthana, Sadiq C Shifana, Maria Joy P, Ajmani Abhishek, Ruby John Anto
Phytochemicals as Potential Lead Molecules against Hepatocellular Carcinoma. Current medicinal chemistry (2024)
Faisal M Athikkavil, Sreekumar U Aiswarya, Remya Johny, Meghna Sudhesh, Amrutha A Nisthul, Ravi S Lankalapalli, Ruby John Anto, Smitha V Bava
A potent bioactive fraction against colon cancer from Plectranthus vettiveroides . Exploration of targeted anti-tumor therapy 4 (2) (2023)
Faisal M Athikkavil, Sreekumar U Aiswarya, Remya Johny, Meghna Sudhesh, Amrutha A Nisthul, Ravi S Lankalapalli, Ruby John Anto, Smitha V Bava
A potent bioactive fraction against colon cancer from Plectranthus vettiveroides . Exploration of targeted anti-tumor therapy 4 (2) (2023)
Daniel L Pouliquen, Koraljka Gall Trošelj, Ruby John Anto
Curcuminoids as Anticancer Drugs: Pleiotropic Effects, Potential for Metabolic Reprogramming and Prospects for the Future. Pharmaceutics 15 (6) (2023)
Faisal M Athikkavil, Sreekumar U Aiswarya, Remya Johny, Meghna Sudhesh, Amrutha A Nisthul, Ravi S Lankalapalli, Ruby John Anto, Smitha V Bava
A potent bioactive fraction against colon cancer from Plectranthus vettiveroides . Exploration of targeted anti-tumor therapy 4 (2) (2023)
Daniel L Pouliquen, Koraljka Gall Trošelj, Ruby John Anto
Curcuminoids as Anticancer Drugs: Pleiotropic Effects, Potential for Metabolic Reprogramming and Prospects for the Future. Pharmaceutics 15 (6) (2023)
Anwar Shabna, Jayesh Antony, Vinod Vijayakurup, Minakshi Saikia, Vijayasteltar B Liju, Archana P Retnakumari, Nisthul A Amrutha, Vijai V Alex, Mundanattu Swetha, Sreekumar U Aiswarya, Somaraj Jannet, Uma Subramanian Unni, Sankar Sundaram, Daisy R Sherin, Nikhil Ponnoor Anto, Smitha V Bava, Sadasivan Chittalakkottu, Sophia Ran, Ruby John Anto
Pharmacological attenuation of melanoma by tryptanthrin pertains to the suppression of MITF-M through MEK/ERK signaling axis. Cellular and molecular life sciences : CMLS 79 (9) (2022)
Mohan Shankar G, Vijai V Alex, Amrutha Nisthul A, Smitha V Bava, Sankar Sundaram, Archana P Retnakumari, Sadasivan Chittalakkottu, Ruby John Anto
Pre-clinical evidences for the efficacy of tryptanthrin as a potent suppressor of skin cancer. Cell proliferation 53 (1) (2019)